Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$3.20 USD
+0.21 (7.02%)
Updated May 1, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Nuvation Bio Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 611 | 661 | 765 | 1 | -99,999 |
Receivables | 4 | 2 | 3 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 2 | 4 | 4 | 0 | NA |
Total Current Assets | 616 | 667 | 772 | 1 | NA |
Net Property & Equipment | 1 | 1 | 1 | 0 | NA |
Investments & Advances | 0 | 0 | 0 | 144 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 1 | 0 | 0 | 0 | NA |
Total Assets | 621 | 672 | 776 | 145 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 2 | 2 | 4 | 3 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 10 | 10 | 12 | 0 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 14 | 13 | 17 | 3 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 1 | 11 | 137 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 16 | 17 | 30 | 140 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | NA |
Common Stock (Par) | 948 | 928 | 910 | 0 | NA |
Capital Surplus | 0 | 0 | 0 | 8 | NA |
Retained Earnings | -343 | -267 | -163 | -3 | NA |
Other Equity | 0 | -6 | -1 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 605 | 655 | 746 | 5 | NA |
Total Liabilities & Shareholder's Equity | 621 | 672 | 776 | 145 | NA |
Total Common Equity | 605 | 655 | 746 | 5 | 0 |
Shares Outstanding | 219.00 | 218.60 | 217.90 | 4.70 | NA |
Book Value Per Share | 2.76 | 3.00 | 3.42 | 1.06 | 0.00 |
Fiscal Year End for Nuvation Bio Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 611 | 619 | 631 | 647 |
Receivables | NA | 4 | 3 | 3 | 2 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 3 | 4 | 4 |
Total Current Assets | NA | 616 | 625 | 637 | 653 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 1 | 1 | 0 | 0 |
Total Assets | NA | 621 | 631 | 641 | 657 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 2 | 3 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 10 | 12 | 10 | 8 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 14 | 16 | 13 | 13 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 16 | 19 | 17 | 16 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 948 | 944 | 938 | 933 |
Capital Surplus | NA | 0 | 0 | 0 | 0 |
Retained Earnings | NA | -343 | -329 | -309 | -289 |
Other Equity | NA | 0 | -3 | -4 | -3 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 605 | 612 | 625 | 641 |
Total Liabilities & Shareholder's Equity | NA | 621 | 631 | 641 | 657 |
Total Common Equity | 0 | 605 | 612 | 625 | 641 |
Shares Outstanding | 218.00 | 219.00 | 218.90 | 218.90 | 218.80 |
Book Value Per Share | 0.00 | 2.76 | 2.79 | 2.85 | 2.93 |